LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,214
تعداد مقالات11,060
تعداد مشاهده مقاله75,094,350
تعداد دریافت فایل اصل مقاله100,138,258
Kasraeian, Maryam, Askari, Fatemeh, Vafaei, Homeira, Asadi, Nasrin, Faraji, Azam, Bazrafshan, Khadijeh, Zare, Marjan. (1404). Rosuvastatin for Improving Fetal Growth Restriction in Pregnant Women: A Double-Blind Randomized Clinical Trial. سامانه مدیریت نشریات علمی, 50(9), 607-617. doi: 10.30476/ijms.2025.103806.3721
Maryam Kasraeian; Fatemeh Askari; Homeira Vafaei; Nasrin Asadi; Azam Faraji; Khadijeh Bazrafshan; Marjan Zare. "Rosuvastatin for Improving Fetal Growth Restriction in Pregnant Women: A Double-Blind Randomized Clinical Trial". سامانه مدیریت نشریات علمی, 50, 9, 1404, 607-617. doi: 10.30476/ijms.2025.103806.3721
Kasraeian, Maryam, Askari, Fatemeh, Vafaei, Homeira, Asadi, Nasrin, Faraji, Azam, Bazrafshan, Khadijeh, Zare, Marjan. (1404). 'Rosuvastatin for Improving Fetal Growth Restriction in Pregnant Women: A Double-Blind Randomized Clinical Trial', سامانه مدیریت نشریات علمی, 50(9), pp. 607-617. doi: 10.30476/ijms.2025.103806.3721
Kasraeian, Maryam, Askari, Fatemeh, Vafaei, Homeira, Asadi, Nasrin, Faraji, Azam, Bazrafshan, Khadijeh, Zare, Marjan. Rosuvastatin for Improving Fetal Growth Restriction in Pregnant Women: A Double-Blind Randomized Clinical Trial. سامانه مدیریت نشریات علمی, 1404; 50(9): 607-617. doi: 10.30476/ijms.2025.103806.3721

Rosuvastatin for Improving Fetal Growth Restriction in Pregnant Women: A Double-Blind Randomized Clinical Trial

Iranian Journal of Medical Sciences
مقاله 3، دوره 50، شماره 9، آذر 2025، صفحه 607-617    اصل مقاله (565.16 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2025.103806.3721
نویسندگان
Maryam Kasraeian1؛ Fatemeh Askari* 1؛ Homeira Vafaei1؛ Nasrin Asadi1؛ Azam Faraji1؛ Khadijeh Bazrafshan2؛ Marjan Zare2
1Maternal-fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Maternal-fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Fetal growth restriction (FGR) results from uteroplacental insufficiency and currently lacks an absolute cure. Statins may offer therapeutic potential by addressing this insufficiency. This study aimed to investigate the effectiveness of rosuvastatin in improving the perinatal outcomes in FGR pregnancies.
Methods: A double-blind, randomized placebo-controlled clinical trial was conducted on 78 FGR pregnancies referred to tertiary centers affiliated with Shiraz University of Medical Sciences (Shiraz, Iran) from January 21, 2023, to March 21, 2023. The participants were randomly divided into two groups using the block randomization method to receive either 5 mg rosuvastatin or placebo daily from FGR diagnosis until delivery. Evaluated outcomes included birth weight, umbilical artery pulsatile index reduction, fetal weight gain, vaginal delivery rate, preterm birth (PTB) incidence, 5-min Apgar score <7, neonatal death, neonatal intensive care unit admission, intraventricular hemorrhage, respiratory distress syndrome, necrotizing enterocolitis, and preeclampsia. The data were analyzed using regression models, reporting mean difference (95% CI), frequency (relative frequency), and odds ratio with 95% confidence interval (OR [95% CI]). Statistical significance was set at P<0.05.
Results: The study included 34 subjects in the rosuvastatin group and 44 subjects in the placebo group, with no significant differences in baseline characteristics. However, the rosuvastatin group showed significantly better outcomes in birth weight (276.27 g, 95% CI=32.61-519.93, OR=1.002, 95% CI=1-1.003), umbilical artery pulsatililty index reduction (0.21 g, 95% CI=0.00-0.43, OR=6.600, 95% CI=1.680-25.930), fetal weight gain (312.51 g, 95% CI=90.50-534.52, OR=1.001, 95% CI=1-1.002), and vaginal delivery rate (6/34 [17.6%] vs. 1/44 [2.3%]; OR=9.210, 95% CI=1.050-80.680). Additionally, the rosuvastatin group had significantly lower PTB rates (15/34 [44.10%] vs. 30/44 [68.20%]; OR=0.370, 95% CI=0.150-0.930). Neonatal health status showed no significant differences between groups.
Conclusion: Rosuvastatin demonstrated improved perinatal outcomes in FGR pregnancies without adverse neonatal effects. 
Trial registration number: IRCT20140317017035N8.

تازه های تحقیق

Maryam Kasraeian (Google Scholar) 

Fatemeh Askari (Google Scholar)

کلیدواژه‌ها
Fetal growth restriction؛ Rosuvastatin calcium؛ Clinical trials, randomized
مراجع
  1. Faraji A, Akbarzadeh-Jahromi M, Bahrami S, Gharamani S, Raeisi Shahraki H, Kasraeian M, et al. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum. J Obstet Gynaecol. 2022;42:900-5. doi: 10.1080/01443615.2021.1955337. PubMed PMID: 34558384.
  2. Faraji A. High level serum Inhibin-A in 1st and 2th pregnancy trimesters as a risk factor for adverse pregnancy outcomes: a systematic review and meta-analysis. Pars Journal of Medical Sciences. 2022;18:25-34. doi: 10.52547/jmj.18.4.4. Persian.
  3. Pels A, Derks J, Elvan-Taspinar A, van Drongelen J, de Boer M, Duvekot H, et al. Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e205323. doi: 10.1001/jamanetworkopen.2020.5323. PubMed PMID: 32585017; PubMed Central PMCID: PMCPMC7301225
  4. Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. J Am Coll Cardiol. 2023;81:1-12. doi: 10.1016/j.jacc.2022.10.013. PubMed PMID: 36351465.
  5. Mendoza M, Ferrer-Oliveras R, Bonacina E, Garcia-Manau P, Rodo C, Carreras E, et al. Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study. Am J Perinatol. 2021;38:1472-9. doi: 10.1055/s-0040-1713651. PubMed PMID: 32615618.
  6. Hirsch A, Ternovsky N, Rotem R. Congenital Anomalies and Statin Exposure During Pregnancy: A systematic review and meta-analysis. American Journal of Obstetrics & Gynecology. 2022;226:S290-S1. doi: 10.1016/j.ajog.2021.11.491.
  7. Bittencourt MS. Statins and Pregnancy - New FDA Recommendations. Arq Bras Cardiol. 2022;119:1-2. doi: 10.36660/abc.20220413. PubMed PMID: 35830095; PubMed Central PMCID: PMCPMC9352124.
  8. Jurisic A, Jurisic Z, Lefkou E, Pombo J, Girardi G. Pravastatin and-L-arginine combination improves umbilical artery blood flow and neonatal outcomes in dichorionic twin pregnancies through an nitric oxide-dependent vasorelaxant effect. Vascul Pharmacol. 2018;110:64-70. doi: 10.1016/j.vph.2018.06.001. PubMed PMID: 29879462.
  9. Brownfoot FC, Tong S, Hannan NJ, Hastie R, Cannon P, Kaitu’u-Lino TJ. Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. BMC Pregnancy Childbirth. 2016;16:117. doi: 10.1186/s12884-016-0902-3. PubMed PMID: 27207105; PubMed Central PMCID: PMCPMC4874016.
  10. Costantine MM. Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome. J Clin Invest. 2016;126:2792-4. doi: 10.1172/JCI89137. PubMed PMID: 27454294; PubMed Central PMCID: PMCPMC4966319.
  11. Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol. 2022;226:S1171-S81. doi: 10.1016/j.ajog.2020.08.040. PubMed PMID: 32818477; PubMed Central PMCID: PMCPMC8237152.
  12. Ma’ayeh M, Rood KM, Kniss D, Costantine MM. Novel Interventions for the Prevention of Preeclampsia. Curr Hypertens Rep. 2020;22:17. doi: 10.1007/s11906-020-1026-8. PubMed PMID: 32052203; PubMed Central PMCID: PMCPMC8237364.
  13. Lefkou E, Mamopoulos A, Dagklis T, Vosnakis C, Rousso D, Girardi G. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest. 2016;126:2933-40. doi: 10.1172/JCI86957. PubMed PMID: 27454295; PubMed Central PMCID: PMCPMC4966313.
  14. Toth PP. An update on the benefits and risks of rosuvastatin therapy. Postgrad Med. 2014;126:7-17. doi: 10.3810/pgm.2014.03.2736. PubMed PMID: 24685964.
  15. Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol. 2016;214:720. doi: 10.1016/j.ajog.2015.12.038. PubMed PMID: 26723196; PubMed Central PMCID: PMCPMC4884459.
  16. LeFevre N, Williamson B, Kolker A, Sundermeyer RL. Common Issues in Prenatal Care: Fetal Growth Restriction. FP Essent. 2023;525:19-23. PubMed PMID: 36780555.
  17. Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56:298-312. doi: 10.1002/uog.22134. PubMed PMID: 32738107.
  18. Society for Maternal-Fetal Medicine . Electronic address pso, Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). Am J Obstet Gynecol. 2020;223:B2-B17. doi: 10.1016/j.ajog.2020.05.010. PubMed PMID: 32407785.
  19. Rosenson RS. Statins: Actions, side effects, and administration. Up Date Database Topic. 2024;4564.
  20. Lindstrom L, Ageheim M, Axelsson O, Hussain-Alkhateeb L, Skalkidou A, Bergman E. Swedish intrauterine growth reference ranges of biometric measurements of fetal head, abdomen and femur. Sci Rep. 2020;10:22441. doi: 10.1038/s41598-020-79797-8. PubMed PMID: 33384446; PubMed Central PMCID: PMCPMC7775468.
  21. Paulson R, Ho J [Internet]. In vitro fertilization: Overview of clinical issues and questions. [Updated: Dec 14, 2024]. Available from: https://www.uptodate.com/contents/in-vitro-fertilization-overview-of-clinical-issues-and-questions?search=In%20vitro%20fertilization%3A%20Overview%20of%20clinical%20issues%20and%20questions%2C%20topic%20last%20updated&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1
  22. Wackernagel D, Gustafsson A, Edstedt Bonamy AK, Reims A, Ahlsson F, Elfving M, et al. Swedish national guideline for prevention and treatment of neonatal hypoglycaemia in newborn infants with gestational age >/=35 weeks. Acta Paediatr. 2020;109:31-44. doi: 10.1111/apa.14955. PubMed PMID: 31350926.
  23. Mandy GTJU, Waltham MA [Internet]. Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality. [Updated: November 19, 2022]. Available from: https://www.uptodate.com/contents/preterm-birth-definitions-of-prematurity-epidemiology-and-risk-factors-for-infant-mortality?search=Preterm%20birth%3A%20Definitions%20of%20prematurity%2C%20epidemiology%2C%20and%20risk%20factors%20for%20infant%20mortality.&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1
  24. Fretts RC, Spong CJU [Internet]. Stillbirth: Incidence, risk factors, etiology, and prevention. [Updated: November 19, 2024]. Available from: https://www.uptodate.com/contents/stillbirth-incidence-risk-factors-etiology-and-prevention?search=Stillbirth%3A%20Incidence%2C%20risk%20factors%2C%20etiology%2C%20and%20prevention&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1
  25. Reis Z, Vitral G, Guimaraes R, Gaspar J, Colosimo E, Taunde S, et al. Premature or Small for Gestational Age Discrimination: International Multicenter Trial Protocol for Classification of the Low-Birth-Weight Newborn Through the Optical Properties of the Skin. JMIR Res Protoc. 2020;9:e16477. doi: 10.2196/16477. PubMed PMID: 32673275; PubMed Central PMCID: PMCPMC7388049.
  26. Barfield WD, Committee On F, Newborn. Standard Terminology for Fetal, Infant, and Perinatal Deaths. Pediatrics. 2016;137. doi: 10.1542/peds.2016-0551. PubMed PMID: 27244834.
  27. Kasraeian M, Asadi N, Vafaei H, Tazang M, Azam F, Rahimirad N, et al. The effect of 150 and 80 mg doses of aspirin on preventing preterm birth in high-risk pregnant women. J Perinat Med. 2022;50:1264-70. doi: 10.1515/jpm-2021-0668. PubMed PMID: 35617440.
  28. Zare M, Faraji A, Nourani Z, Askary E, Kasraeian M. Neutrophil-Lymphocyte Ratio as a screening test for preeclampsia in the first and early-third trimesters of pregnancy: A cohort study. Galen Medical Journal. 2022;11:e2433. doi: 10.31661/gmj.v11i.2433.
  29. Bakker OJ, van Santvoort HC, van Brunschot S, Ahmed Ali U, Besselink MG, Boermeester MA, et al. Pancreatitis, very early compared with normal start of enteral feeding (PYTHON trial): design and rationale of a randomised controlled multicenter trial. Trials. 2011;12:73. doi: 10.1186/1745-6215-12-73. PubMed PMID: 21392395; PubMed Central PMCID: PMCPMC3068962.
  30. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J, Jr. Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res. 2010;33:892-8. doi: 10.1038/hr.2010.92. PubMed PMID: 20535121.
  31. Hirsch A, Rotem R, Ternovsky N, Hirsh Raccah B. Pravastatin and placental insufficiency associated disorders: A systematic review and meta-analysis. Front Pharmacol. 2022;13:1021548. doi: 10.3389/fphar.2022.1021548. PubMed PMID: 36438820; PubMed Central PMCID: PMCPMC9682185.
آمار
تعداد مشاهده مقاله: 363
تعداد دریافت فایل اصل مقاله: 94


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب